| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
L-Isoleucine-13C6,15N targets the same biological pathways as unlabeled L-isoleucine, serving as a substrate for protein synthesis and various metabolic pathways. As a stable isotope-labeled amino acid, it is incorporated into proteins and metabolites in the same way as the unlabeled form. The compound is used to trace the metabolism of isoleucine in cells and organisms. Isoleucine is an essential amino acid that plays critical roles in protein synthesis, glucose metabolism, and immune function. The 13C and 15N labels allow for precise tracking of the amino acid through metabolic pathways using mass spectrometry. The compound is used in studies of amino acid metabolism, protein turnover, and nutritional research. The isotopic labels do not alter the biological activity of the amino acid but allow for its detection and quantification in complex biological samples.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [2].
In vitro, L-Isoleucine-13C6,15N is used as a tracer in cell culture experiments to study amino acid metabolism and protein synthesis. The compound is added to cell culture media at concentrations similar to those of unlabeled isoleucine (typically 0.1-1 mM). Cells take up the labeled amino acid and incorporate it into proteins and metabolites. The labeled compounds are then detected and quantified using mass spectrometry. This allows researchers to measure protein synthesis rates, track metabolic fluxes, and identify metabolic pathways. In SILAC experiments, L-Isoleucine-13C6,15N is used to label proteins in cell culture for quantitative proteomics. The compound's stable isotopes provide a mass shift that allows for the differentiation of labeled and unlabeled peptides in mass spectra. The compound is also used in studies of amino acid transporters and metabolism. |
| ln Vivo |
In vivo, L-Isoleucine-13C6,15N is used as a tracer in animal studies to study amino acid metabolism, protein turnover, and metabolic flux. The compound is administered orally, intravenously, or intraperitoneally to animals. Blood, tissue, and urine samples are collected at various time points and analyzed by mass spectrometry. The isotopic labels allow for the precise quantification of isoleucine metabolism and its incorporation into proteins. The compound is used in studies of amino acid requirements, metabolic disorders, and nutritional research. In clinical research, stable isotope-labeled amino acids are used to study human metabolism and protein turnover. The compound is not used as a therapeutic agent but as a research tool. The compound is typically administered at tracer doses that do not affect normal metabolism.
|
| Enzyme Assay |
In vitro experiments with L-Isoleucine-13C6,15N typically involve adding the compound to cell culture media at concentrations of 0.1-1 mM. Cells are cultured in media containing the labeled amino acid for 24-72 hours to allow for incorporation into proteins and metabolites. After incubation, cells are harvested, and proteins are extracted and digested with trypsin. The resulting peptides are analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The isotopic labels provide a mass shift that allows for the identification and quantification of labeled peptides. For metabolic flux analysis, cells are treated with the labeled amino acid, and metabolites are extracted and analyzed by mass spectrometry. The compound is typically dissolved in water or cell culture medium. For long-term storage, the powder is kept at room temperature or -20°C.
|
| Cell Assay |
In vitro cell-based assays using L-Isoleucine-13C6,15N are typically performed in cell culture systems for metabolic labeling studies. Cells are cultured in media containing the labeled amino acid for 24-72 hours. The labeled amino acid is incorporated into newly synthesized proteins, allowing for the measurement of protein synthesis rates. For SILAC experiments, cells are cultured in media containing L-Isoleucine-13C6,15N for at least 5-6 cell doublings to ensure complete labeling. After labeling, cells are harvested, proteins are extracted, and analyzed by mass spectrometry. The isotopic labels allow for the quantification of protein abundance and turnover. The compound can also be used to study amino acid metabolism by tracking the incorporation of the label into metabolic intermediates. Cells are typically cultured in standard conditions (37°C, 5% CO2) in appropriate media.
|
| Animal Protocol |
In vivo animal experiments with L-Isoleucine-13C6,15N involve administering the compound to animals to study amino acid metabolism and protein turnover. The compound is typically administered orally, intravenously, or intraperitoneally at tracer doses (typically 1-100 mg/kg). Blood samples are collected at various time points (0-24 hours) to measure the disappearance of the labeled amino acid from the circulation. Tissue samples (liver, muscle, brain, etc.) are collected at the end of the experiment and analyzed by mass spectrometry. The isotopic labels allow for the quantification of isoleucine incorporation into proteins and metabolic intermediates. The compound is used in studies of protein synthesis rates, amino acid requirements, and metabolic disorders. In clinical research, the compound may be administered to human subjects to study metabolism. The compound is typically formulated in saline or water for administration.
|
| ADME/Pharmacokinetics |
L-Isoleucine-13C6,15N has similar pharmacokinetic properties to unlabeled L-isoleucine. The compound is absorbed from the gastrointestinal tract after oral administration and is distributed to tissues via the bloodstream. Isoleucine is transported into cells by amino acid transporters and is used for protein synthesis or metabolized through various pathways. The compound's isotopic labels do not alter its pharmacokinetic properties. In metabolic studies, blood samples are collected at various time points to measure the disappearance of the labeled amino acid from the circulation. The compound's half-life in plasma is typically 1-2 hours in humans. Isoleucine is metabolized primarily in the liver and muscle through the branched-chain amino acid degradation pathway. The compound is stored as a powder at room temperature or -20°C for long-term storage. In solution, it is stable for short periods at 4°C.
|
| Toxicity/Toxicokinetics |
L-Isoleucine-13C6,15N has low toxicity as it is a stable isotope-labeled form of an essential amino acid. The compound is intended for research use only and is not for human consumption. When used as a tracer in metabolic studies, the compound is administered at very low doses that do not affect normal metabolism. The compound is not classified as a hazardous substance. Standard laboratory safety precautions should be followed when handling the compound, including the use of gloves and eye protection. The compound is stable under normal storage conditions. As an essential amino acid, isoleucine is naturally present in the diet and is generally recognized as safe. The isotopic labels (13C and 15N) are stable and non-radioactive, posing no radiation hazard. The compound should be handled in a well-ventilated area. Safety data sheets recommend standard handling procedures for research chemicals.
|
| References |
[1]. Arkhipov SG, et al. New hydrophobic L-amino acid salts: maleates of L-leucine, L-isoleucine and L-norvaline. Acta Crystallogr C Struct Chem. 2015 Jul;71(Pt 7):584-92.
[2]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. |
| Additional Infomation |
L-Isoleucine-13C6,15N (CAS 202468-35-7) is a stable isotope-labeled form of the essential amino acid L-isoleucine. It contains six carbon-13 (13C) atoms and one nitrogen-15 (15N) atom. The compound has the molecular formula 13C6H13NO2 and a molecular weight of approximately 138.15 g/mol. L-Isoleucine is one of the three branched-chain amino acids (BCAAs) along with leucine and valine. The isotope-labeled form is used in mass spectrometry-based metabolomics and proteomics studies for quantitative analysis. It is used in stable isotope labeling by amino acids in cell culture (SILAC) experiments for protein quantification. The compound is used to trace the metabolism of isoleucine in cells and organisms. Isoleucine plays critical roles in protein synthesis, glucose metabolism, and immune function. The 13C and 15N labels allow for precise tracking of the amino acid through metabolic pathways using mass spectrometry. The compound is intended for research use only and is not for human consumption. It is typically stored as a powder at room temperature or -20°C for long-term storage.
|
| Molecular Formula |
C6H13NO2
|
|---|---|
| Molecular Weight |
138.1223
|
| Exact Mass |
138.111
|
| CAS # |
202468-35-7
|
| Related CAS # |
L-Isoleucine;73-32-5
|
| PubChem CID |
101365133
|
| Appearance |
White to off-white solid powder
|
| LogP |
-1.7
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
9
|
| Complexity |
103
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
[13CH3][13CH2][13C@H]([13CH3])[13C@@H]([13C](=O)O)[15NH2]
|
| InChi Key |
AGPKZVBTJJNPAG-PVHYACKGSA-N
|
| InChi Code |
InChI=1S/C6H13NO2/c1-3-4(2)5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t4-,5-/m0/s1/i1+1,2+1,3+1,4+1,5+1,6+1,7+1
|
| Chemical Name |
(2S,3S)-2-(15N)azanyl-3-(113C)methyl(1,2,3,4,5-13C5)pentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.2401 mL | 36.2004 mL | 72.4008 mL | |
| 5 mM | 1.4480 mL | 7.2401 mL | 14.4802 mL | |
| 10 mM | 0.7240 mL | 3.6200 mL | 7.2401 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
